In 1998, Organogenesis Inc. received approval for its first allogeneic product, Apligraf, from the FDA's Center for Devices and Radiological Health (CDRH). Read More
With big pharma's flight from central nervous system (CNS) drug discovery, one conclusion of a recent Tufts report seems surprising on first read: The CNS new product pipeline is among the richest in the research-based drug industry. Read More
